A first-in-human, phase I, single-center, open-label, dose-escalation trial in healthy volunteers to assess safety, tolerability, and immunogenicity of PANHPVAX, a vaccine targeting human papilloma L2 antigen formulated with cyclic di-AMP

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511493-67-00

Enrollment

Registered

2024-06-06

Start date

2022-10-07

Completion date

Unknown

Last updated

2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prophylactic vaccination against HPV in healthy volunteers

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Germany

None listed

Source: EU CTIS · Data processed: Feb 4, 2026